

NRC Publications Archive Archives des publications du CNRC

Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against *Clostridium difficile*-associated disease

Kandalaft, Hiba; Hussack, Greg; Aubry, Annie; van Faassen, Henk; Guan, Yonghong; Arbabi-Ghahroudi, Mehdi; Mackenzie, Roger; Logan, Susan M.; Tanha, Jamshid

This publication could be one of several versions: author's original, accepted manuscript or the publisher's version. / La version de cette publication peut être l'une des suivantes : la version prépublication de l'auteur, la version acceptée du manuscrit ou la version de l'éditeur.

For the publisher's version, please access the DOI link below. / Pour consulter la version de l'éditeur, utilisez le lien DOI ci-dessous.

Publisher's version / Version de l'éditeur:

<https://doi.org/10.1007/s00253-015-6594-1>

Applied Microbiology and Biotechnology, 99, 20, pp. 8549-8562, 2015-05-05

NRC Publications Archive Record / Notice des Archives des publications du CNRC :

<https://nrc-publications.canada.ca/eng/view/object/?id=b403760a-7c94-4eaa-8d4f-b5611feb6453>

<https://publications-cnrc.canada.ca/fra/voir/objet/?id=b403760a-7c94-4eaa-8d4f-b5611feb6453>

Access and use of this website and the material on it are subject to the Terms and Conditions set forth at

<https://nrc-publications.canada.ca/eng/copyright>

READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS WEBSITE.

L'accès à ce site Web et l'utilisation de son contenu sont assujettis aux conditions présentées dans le site

<https://publications-cnrc.canada.ca/fra/droits>

LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D'UTILISER CE SITE WEB.

Questions? Contact the NRC Publications Archive team at

PublicationsArchive-ArchivesPublications@nrc-cnrc.gc.ca. If you wish to email the authors directly, please see the first page of the publication for their contact information.

Vous avez des questions? Nous pouvons vous aider. Pour communiquer directement avec un auteur, consultez la première page de la revue dans laquelle son article a été publié afin de trouver ses coordonnées. Si vous n'arrivez pas à les repérer, communiquez avec nous à PublicationsArchive-ArchivesPublications@nrc-cnrc.gc.ca.

Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against *Clostridium difficile*-associated disease

Hiba Kandalafi¹ · Greg Hussack¹ · Annie Aubry¹ · Henk van Faassen¹ ·
Yonghong Guan¹ · Mehdi Arbabi-Ghahroudi^{1,2,3} · Roger MacKenzie^{1,3} ·
Susan M. Logan^{1,4} · Jamshid Tanha^{1,3,4}

Received: 25 February 2015 / Revised: 1 April 2015 / Accepted: 5 April 2015 / Published online: 5 May 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract *Clostridium difficile* is a leading cause of death from gastrointestinal infections in North America. Antibiotic therapy is effective, but the high incidence of relapse and the rise in hypervirulent strains warrant the search for novel treatments. Surface layer proteins (SLPs) cover the entire *C. difficile* bacterial surface, are composed of high-molecular-weight (HMW) and low-molecular-weight (LMW) subunits, and mediate adherence to host cells. Passive and active immunization against SLPs has enhanced hamster survival, suggesting that antibody-mediated neutralization may be an effective therapeutic strategy. Here, we isolated a panel of SLP-specific single-domain antibodies (V_HHs) using an immune llama phage display library and SLPs isolated from *C. difficile* hypervirulent strain QCD-32g58 (027 ribotype) as a target antigen. Binding studies revealed a number of V_HHs that bound QCD-32g58 SLPs with high affinity ($K_D=3-6$ nM) and targeted epitopes located on the LMW subunit of the SLP. The V_HHs demonstrated

melting temperatures as high as 75 °C, and a few were resistant to the gastrointestinal protease pepsin at physiologically relevant concentrations. In addition, we demonstrated the binding specificity of the V_HHs to the major *C. difficile* ribotypes by whole cell ELISA, where all V_HHs were found to bind 001 and 027 ribotypes, and a subset of antibodies were found to be broadly cross-reactive in binding cells representative of 012, 017, 023, and 078 ribotypes. Finally, we showed that several of the V_HHs inhibited *C. difficile* QCD-32g58 motility in vitro. Targeting SLPs with V_HHs may be a viable therapeutic approach against *C. difficile*-associated disease.

Keywords *Clostridium difficile* · Surface layer protein · Single-domain antibody · V_HH · Nanobody

Introduction

Clostridium difficile is currently the leading hospital-acquired infection in developed countries (Karas et al. 2010). As a Gram-positive, anaerobic, endospore-forming gastrointestinal (GI) pathogen, the bacterium causes *C. difficile*-associated disease (CDAD) in humans and animals. Symptoms of CDAD range from mild antibiotic-associated diarrhea to pseudomembranous colitis and death, with an estimated associated health care cost of \$3.2 billion annually in the USA (Dubberke and Olsen 2012; Ghantouji et al. 2010). From 2002 to 2005, the Canadian province of Québec suffered a CDAD epidemic, largely associated with a predominant strain referred to as North American pulsed-field type 1 (NAP1), ribotype 027, toxinotype III, and restriction endonuclease group BI (Bourgault et al. 2006; Gilca et al. 2010; Hubert et al. 2007; Loo et al. 2005; Pépin et al. 2004; Warny et al. 2005). These ribotype 027 strains were undetected in 2000

This is National Research Council Canada publication 53299.

Electronic supplementary material The online version of this article (doi:10.1007/s00253-015-6594-1) contains supplementary material, which is available to authorized users.

✉ Jamshid Tanha
jamshid.tanha@nrc-cnrc.gc.ca

- ¹ Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON K1A 0R6, Canada
- ² Department of Biology, Carleton University, Ottawa, ON K1S 5B6, Canada
- ³ School of Environmental Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada
- ⁴ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada

and 2001 but were responsible for the Québec outbreak in which its prevalence was estimated at 75.2 % of all polymerase chain reaction (PCR)-ribotyped strains in 2003 (MacCannell et al. 2006). Québec strain QCD-32g58 (NZ_CM000287.1) is one such isolate belonging to this group. Strains within PCR ribotype 027 have evolved to produce elevated levels of toxins A and B (Dupuy et al. 2008; Warny et al. 2005), have acquired antibiotic resistance cassettes (Bourgault et al. 2006; Pépin et al. 2005; Schmidt et al. 2007; Spigaglia et al. 2008; Stabler et al. 2009), and have shown enhanced sporulation ability (Åkerlund et al. 2008), all of which contribute to their virulence. Toxins A and B (TcdA and TcdB) are the primary *C. difficile* virulence factors and are therapeutic targets (Giannasca and Warny 2004; Hussack and Tanha 2010; Jank and Aktories 2008; Jank et al. 2007); however, targeting other virulence factors such as surface layer proteins (SLPs), cell wall proteins, and flagellar components have also been proposed as therapeutic strategies (Ghose 2013).

SLPs are common to almost all Archaea and can be found in nearly every phylogenetic group within Eubacteria (Fagan and Fairweather 2014; Sleytr and Beveridge 1999). These proteins have been identified as virulence factors for bacteria such as *Campylobacter fetus* and *Aeromonas salmonicida*, providing the cells with structural integrity, acting as molecular sieves and playing a role in adherence and immune evasion (Grogono-Thomas et al. 2000; Hamadeh et al. 1995; Sara and Sleytr 2000). *C. difficile* produces unique SLPs in that they are cleaved from a common precursor, SlpA, to generate the HMW and LMW subunits (Calabi et al. 2001). The two subunits associate to form mature proteins that cover the entire surface of the bacterium in a para-crystalline layer. The LMW subunit is highly immunogenic (Pantosti et al. 1989), is surface exposed (Fagan et al. 2009), and exhibits low inter-strain identity among different PCR ribotypes (Calabi and Fairweather 2002; Spigaglia et al. 2011). The high variability observed could be due to a lack of functional constraints or the evolutionary need to evade host immune responses. Indeed, *C. difficile* SLPs play a critical role in bacterial adherence to host cells (Calabi et al. 2002; Drudy et al. 2001; Merrigan et al. 2013; Takumi et al. 1991) and thereby contribute to colonization and the persistence of infection. They have also been shown to perturb cytokine homeostasis and modulate immune responses (Ausiello et al. 2006; Bianco et al. 2011; Collins et al. 2014; Ryan et al. 2011). SLPs induce maturation of dendritic cells and the subsequent generation of a T-helper cell response through Toll-like receptor 4 (TLR4), thereby altering host inflammatory and regulatory cytokines toward an inflammatory state and contributing to the damage of the intestinal epithelium. Interestingly, human patients with relapsing *C. difficile* incidences were found to exhibit a lower immunoglobulin M (IgM) response to SLPs compared to patients with a single *C. difficile* episode (Drudy et al. 2004), suggesting that the ability to mount an anti-SLP antibody

response may significantly determine a patient's disease state. Collectively, these studies support the hypothesis of an important role for SLPs in innate and adaptive immunity.

A limited number of examples suggest targeting SLPs could be a potential therapeutic approach to combat CDAD. O'Brien et al. (2005) demonstrated that prophylactic administration of SLP anti-sera significantly prolonged survival of hamsters that were lethally challenged. Subsequent studies of active immunization of mice using crude cell wall extracts showed a significant reduction in *C. difficile* colonization of the immunized group compared to controls (Péchiné et al. 2007). Currently, *C. difficile* infections are treated with a course of antibiotics, which can alter the composition of the gut microbiome and increase the selection pressure on the organism, which can in turn lead to antibiotic resistance. Targeting essential bacterial virulence factors, such as SLPs, is an alternative therapeutic strategy to conventional antibiotic use, which can address the risk of rising antibiotic resistance (Cegelski et al. 2008; Clatworthy et al. 2007; Lynch and Wiener-Kronish 2008).

Single-domain antibodies isolated from the variable domains of Camelidae species heavy-chain IgGs (referred to as V_HHs or "Nanobodies") are attractive candidates to explore for oral therapy because these domains retain the affinity and specificity of conventional monoclonal antibodies (mAbs), but possess added biophysical advantages such as resistance to extreme pH and proteases (Harmsen and De Haard 2007; Holliger and Hudson 2005; Holt et al. 2003). Single-domain antibodies have been isolated to many targets in the context of infection and immunity (Hussack and Tanha 2010; Wesolowski et al. 2009), and their potential as oral therapeutics has been well documented (Harmsen et al. 2007; van der Vaart et al. 2006; Viridi et al. 2013).

The use of antibodies as neutralizing agents, in addition to studies implicating *C. difficile* SLPs as mediators for cell-host interactions (Calabi et al. 2002; Drudy et al. 2001), has inspired the current study. Here, V_HHs to SLPs from *C. difficile* strain QCD-32g58 were selected from an immune llama V_HH phage display library. The antibodies were then functionally and biochemically characterized with respect to structure, affinity, specificity, aggregation state, thermostability, resistance to pepsin digestion, and the ability to bind and inhibit the motility of *C. difficile* cells.

Materials and methods

Isolation of SLPs from *C. difficile* strains 630 and QCD-32g58

C. difficile SLPs were isolated using low-pH glycine extraction as described previously (Dubreuil et al. 1988) with the following modifications. Briefly, cells from strains QCD-32g58 (GenBank accession no. AAML00000000; Janvilisri

et al. 2009; Forgetta et al. 2011) and 630 (GenBank accession no. AM180355.1; Janvilisri et al. 2009; Monot et al. 2011; Sebahia et al. 2006) were cultured overnight on a BHI-agar plate, scraped, resuspended in 500 μ l of 0.2 M glycine, pH 2.2, and incubated for 10 min at room temperature. Bacterial cells were removed by centrifugation at 13,000 rpm in a benchtop centrifuge and the SLP-containing supernatant transferred to a 4-ml Amicon filter device with a 5000 Da MWCO (EMD Millipore, Toronto, ON, Canada) for buffer exchange. The SLPs were washed twice with 4 ml of sterile H₂O and collected in 1 ml sterile H₂O. A 10- μ l aliquot was mixed with SDS-PAGE loading buffer containing β -mercaptoethanol and analyzed on a 12.5 % SDS-PAGE gel. Size-exclusion chromatography (SEC) was used to further purify the isolated SLP proteins after extraction. To this end, a Superdex™ 200 10/30 GL column (GE Healthcare, Baie-d'Urfé, QC, Canada) was equilibrated with running buffer (10 mM HEPES buffer, pH 7.5, 150 mM NaCl), and 500 μ l of SLP extracts were loaded and eluted over one column volume as previously described (Fagan et al. 2009). Eluted fractions were analyzed on a 12.5 % SDS-PAGE for content. All fractions were stored at 4 °C for later use.

Llama immunization, V_HH phage display library construction, and panning

Llama immunization, library construction, and panning were carried out as described previously (Hussack et al. 2012). Briefly, for llama immunization, one adult male llama (*Lama glama*) was immunized subcutaneously four times at its lower back with a mixture of QCD-32g58 and 630 SLP antigens at the Cedarlane animal facility (Burlington, ON, Canada) and according to the company's animal safety protocol. On the first day, a pre-immune bleed was conducted and a mixture of two antigens (100 μ g of each antigen diluted in PBS in total volume of 1.25 ml) and Freund's complete adjuvant (1.25 ml; Sigma, Oakville, ON, Canada) was injected into the llama. The llama received three additional boosts with 100 μ g of the same antigen mixture with Freund's incomplete adjuvant (Sigma) on days 28, 47, and 66. Blood (10–15 ml) was collected on days 59 and 72. Total (un-fractionated) serum was analyzed for a specific response to QCD-32g58 and 630 SLPs by enzyme-linked immunosorbent assay (ELISA). Llama serum from day 72 was fractionated into conventional (IgG1) and heavy-chain antibody (IgG2 and IgG3) components and analyzed for specific binding to QCD-32g58 and 630 SLPs by ELISA (Hussack et al. 2012). Lymphocytes were isolated at Cedarlane. A V_HH phage display library was constructed using approximately 2×10^7 lymphocytes (as the source of V_HH repertoire genes) collected from the day 72 blood. The size of the library was estimated to be 2.7×10^8 transformants. The V_HH DNA fragments from 92 colonies were PCR-amplified and sequenced to assess library diversity. Library

phage was prepared and 10^{12} colony-forming units (CFU) of library phage was used as input for the first round of panning against 10 μ g of SEC-purified QCD-32g58 SLPs coated onto NuncMaxisorp™ wells (Thermo Fisher, Ottawa, ON, Canada). For the following three rounds of panning, 10^{11} CFU phage was used as the input. Phage ELISA was performed to identify individual phage displaying V_HHs specific to QCD-32g58 and 630.

V_HH subcloning, soluble expression, purification, and SEC

Positive V_HH binders identified by phage ELISA were subcloned, expressed in 1-l cultures and purified by immobilized metal-ion affinity chromatography as described (Hussack et al. 2012). Purified proteins were assessed for purity and integrity by SDS-PAGE. The aggregation status and elution volumes of V_HHs were determined by SEC using a Superdex™ 75 10/300 GL column (GE Healthcare) as described (Hussack et al. 2012; Kim et al. 2012a). Elution volumes were used to determine apparent molecular masses (M_{app}) of V_HHs from a set of protein standards (Hussack et al. 2011b). SEC chromatograms were normalized as described (Kim et al. 2012b).

SPR analysis

The binding of all V_HHs to immobilized QCD-32g58 SLP, 630 SLP, and QCD-32g58 SLP LMW subunit was determined by surface plasmon resonance (SPR) using a Biacore 3000 (GE Healthcare). The SLPs were SEC-purified as described above prior to immobilization at concentrations of 50 μ g/ml in 10 mM acetate buffer on a CM5 sensor chip using the amine coupling kit supplied by the manufacturer (GE Healthcare). In all instances, analyses were carried out at 25 °C in 10 mM HEPES running buffer, pH 7.4, containing 150 mM NaCl, 3 mM EDTA, and 0.005 % surfactant P20 at a flow rate of 20 μ l/min. For regeneration, the surfaces were washed thoroughly with either running buffer (SLP_V_HH2, SLP_V_HH26, SLP_V_HH49, and SLP_V_HH50), 10 mM glycine-HCl, pH 3.0, for 3 s (SLP_V_HH22), 10 mM glycine-HCl, pH 2.5, for 3 s (SLP_V_HH5 and SLP_V_HH46), or 50 mM NaOH for 3 s (SLP_V_HH12 and SLP_V_HH23). Due to the loss of surface activity after 50 mM NaOH surface regeneration, a fresh surface was made and used to study the binding activity of SLP_V_HH12 and SLP_V_HH23. Data were analyzed with BIAevaluation 4.1 software.

T_m measurements by circular dichroism spectroscopy

The thermal unfolding profile of each antibody was obtained using circular dichroism (CD) according to a previously described method (Hussack et al. 2011b) with minor modifications. Briefly, after dialysis into 10 mM sodium phosphate

buffer, pH 7.0, a 1-mm cuvette containing 200 μ l of a V_{HH} at 50 μ g/ml was used to obtain CD spectra from 180–260 nm using a J-810 spectropolarimeter (Jasco Inc., Easton, MD, USA). The temperature was increased from 30 to 96 °C at a temperature ramp rate of 1 °C/min, and data were collected every 2 °C at a spectral scan rate of 50 nm/min and 1-mm bandwidth.

Disulfide bond mapping by MS

Disulfide bond mapping of SLP_ $V_{\text{HH}}\text{H22}$ and SLP_ $V_{\text{HH}}\text{H50}$, each with four Cys residues, was performed essentially as described (Kim et al. 2012b; Hussack et al. 2011b). Briefly, tryptic fragments for subsequent mass spectrometry (MS) analysis were prepared as described (Kim et al. 2012a). Aliquots of V_{HH} proteolytic digests were resuspended in 0.1 % (v/v) formic acid (aq) and analyzed by nanoflow reversed-phase HPLC MS (nanoRPLC-ESI-MS) with data-dependent analysis (DDA) using collision-induced dissociation (CID) on a nanoAcquity UPLC system coupled to a Q-TOF Ultima™ hybrid quadrupole/TOF mass spectrometer (Waters, Milford, MA, USA). The peptides were first loaded onto a 300 μ m I.D. \times 5 mm C18 PepMap100 μ -precolum (Thermo Fisher) and then eluted into a 100 μ m I.D. \times 10 cm 1.7- μ m BEH130C18 column (Waters) using a linear gradient from 0 to 36 % solvent B (acetonitrile+0.1 % formic acid) over 36 min followed by 36–90 % solvent B for 2 min. Solvent A was 0.1 % formic acid in water. The peptide MS² spectra were compared with V_{HH} protein sequences using the Mascot™ database searching algorithm (Matrix Science, London, UK). The MS² spectra of the disulfide-linked peptides were de-convoluted using the MaxEnt 3 program (Waters) for de novo sequencing to confirm and/or determine the exact disulfide linkage positions.

Pepsin digestion assay

To assess the degree of resistance of each antibody to pepsin (a common protease in the digestive tract), SLP-specific V_{HH} s were subjected to pepsin digestion as previously described (Hussack et al. 2011b) at enzyme concentrations ranging from 1.25 to 100 μ g/ml. Triplicate independent experiments were conducted, and densitometry analysis values were averaged to determine percent pepsin resistance.

Epitope characterization by Western blot analysis

To determine subunit specificity of the V_{HH} s and the nature of their epitope (conformational or linear), denaturing Western blots of strain QCD-32g58 SLPs were probed with anti-SLP V_{HH} s. SLPs (5 μ g/lane) were separated on 12.5 % SDS-PAGE gels and transferred to PVDF membranes at 100 V for 1 h. Membranes were blocked for 2 h with 2 % (w/v) milk

in PBS and probed with various V_{HH} s (50 μ g/5 ml PBS-T [PBS/0.05 % (v/v) Tween 20]) for 1 h. Membranes were washed three times in PBS-T followed by addition of mouse anti-His IgG-alkaline phosphatase (AP) conjugate (Abcam, Cambridge, MA, USA), diluted 1:5000 in blocking buffer, for 1 h. Membranes were washed as before and subjected to AP substrate (Bio-Rad, Mississauga, ON, Canada) for 10 min, washed in distilled H₂O and air dried. A corresponding stained SDS-PAGE gel of the SLPs was used as reference.

Whole cell ELISA

C. difficile strains were grown on BHI supplemented agar under anaerobic conditions at 37 °C overnight. Cells were resuspended in PBS containing 3 % (v/v) formalin and left for 24 h at 4 °C. Cells were washed two times with PBS and resuspended to OD₆₀₀ 0.08. NuncMaxiSorp® Flat-Bottom plates were coated with 100 μ l of formalin-fixed cells overnight at 37 °C. Plates were blocked with 2 % (w/v) milk in PBS. His₆-tagged V_{HH} s specific for SLP were then added (10 μ g/ml in PBS-T) and plates incubated at 37 °C for 1 h in a shaker incubator. Plates were washed three times with PBS-T and then incubated with rabbit anti-His₆ antibody-horse radish peroxidase conjugate (1:5,000 in PBS-T, of a 1 mg/ml stock; Cedarlane) for 1 h at 37 °C. Following washing as above, the antibody was detected with TMB substrate for 10 min and the reaction stopped with 1 M H₃PO₄. Samples were analyzed in triplicate, and the absorbance was measured at 450 nm.

Motility assay

An in vitro motility assay was used to determine if the isolated V_{HH} s were capable of binding whole *C. difficile* cells and preventing motility. Sterile culture tubes containing 5 ml 0.175 % agar-BHI media supplemented with 0.5 % (w/v) Bacto-yeast extract, 0.12 % (w/v) NaCl, and 25 or 50 μ g/ml V_{HH} , were stabbed with a fresh culture of strain QCD-32g58 as previously described (Twine et al. 2009) and incubated in anaerobic conditions at 37 °C for 23 h. Photographs were taken at 23 h postinoculation to monitor the effects of each antibody on motility of the strain relative to a control which did not receive antibody.

Results

Purification of SLPs from 630 and QCD-32g58 *C. difficile* strains

SLPs from *C. difficile* strains 630 and QCD-32g58 (Figs. 1a and S1) were first purified by low pH glycine extraction. When analyzed by reducing SDS-PAGE, the HMW and




Fig. 1 Isolation of SLP-specific V_H Hs. **a** Schematic diagram of *C. difficile* S-layer proteins. *Top*, SLP low-molecular-weight (LMW) and high-molecular-weight (HMW) subunits are expressed as a single polypeptide chain before cleavage with Cwp84 cysteine protease. The cleavage site of the signal sequence (SS) is also shown. *Bottom*, after Cwp84-mediated cleavage, the LMW and HMW subunits associate in the orientation relative to the bacterial cell wall shown. **b** SDS-PAGE, run under reducing (R) conditions, of SLPs purified from 630 and QCD-32g58 (QCD) strains using low pH extraction. **c** *Left*, SEC SuperdexTM 200 profile of SLPs and, *right*, reducing SDS-PAGE gel of the corresponding fractions. Only LMW subunit from QCD-32g58 could

be purified (shown with an *asterisk*). The HMW subunit could not be purified from either strain. **d** Work flow overview and llama immunization schedule for the isolation of SLP-specific V_H Hs. *FCA* Freund's complete adjuvant, *FIA* Freund's incomplete adjuvant, *Ag* QCD-32g58 SLP. **e** Phage ELISA demonstrating the binding of phage-displayed V_H Hs to immobilized SLPs. **f** Amino acid sequence alignment of V_H Hs isolated from panning that were expressed and characterized in this study. Positions 42, 49, 50, 52, and 55 are numbered. Numbering and CDR designations are according to IMGT (<http://imgt.cines.fr/>). **g** Unusual disulfide bonds (DSB) identified in SLP_ V_H H22 and SLP_ V_H H50 by mass spectrometry fingerprinting analysis

LMW SLPs migrated to ~45 and ~33 kDa (630) and ~45 and ~34 kDa (QCD-32g58) (Fig. 1b), which is close to the predicted *M*s of 39.5/34.2 kDa and 44.2/33.9 kDa (HMW/LMW SLPs, from 630 and QCD-32g58 strains, respectively) and consistent with others who ran SLPs under reducing SDS-PAGE conditions (Calabi et al. 2001; Mauri et al. 1999). To increase SLP purity, low pH extracted-SLP preparations were injected over a SuperdexTM 200 SEC column (Fig. 1c, left panel). Fractions from the two major peaks and one minor peak were analyzed by 12.5 % SDS-PAGE (Fig. 1c, right panel). The first peak (with an elution volume of 10.8 ml), when analyzed by SDS-PAGE, confirmed the presence of

both HMW and LMW subunits of SLPs. The second minor peak eluting at approximately 15 ml corresponded to the LMW subunit. The LMW subunit could only be isolated from QCD-32g58. The last major SEC peak was not detectable on SDS-PAGE despite the strong A_{280nm} signal, which could represent breakdown products of the HMW subunit, as it is unstable once separated from the LMW subunit (Fagan et al. 2009), and since the HMW subunit was not isolated in free-form from any of the fractions collected. The SEC-purified QCD-32g58 SLP and LMW SLP were used in library panning and SPR experiments.

Llama immunization, library construction, and panning for SLP-binding V_HHs

V_HHs isolated from naive libraries tend to have low target antigen affinities (K_{DS} in the μM range; Tanha et al. 2002; Yau et al. 2005); therefore, an immune llama library was constructed to isolate high affinity binders to SLPs, using a mixture of 630 and QCD-32g58 SLPs as immunogens. A male llama was immunized using an equal mixture of both antigens, according to the schedule in Fig. 1d. Llama sera and blood were processed and a heavy-chain IgG response to QCD-32g58 SLP was determined by ELISA (data not shown). An immune phage display library was constructed and was subjected to four rounds of panning against SLPs from QCD-32g58 (Fig. 1d). To identify QCD-32g58-specific binders after three rounds of panning, a total of 50 TG1 *E. coli* colonies containing the phagemid vector were picked at random for monoclonal phage ELISA to identify binders to QCD-32g58 SLP (data not shown). Nine unique V_HHs were identified, and the phage ELISA is shown for those clones (Fig. 1e). The amino acid sequence composition of the nine unique antibodies (Fig. 1f) confirmed their identity as V_HHs (not V_HS), according to characteristic camelid V_HH residues at positions 42, 49, 50, and 52 (Harmsen et al. 2000). The V_HHs were denoted SLP_V_HH2, SLP_V_HH5, SLP_V_HH12, SLP_V_HH22, SLP_V_HH23, SLP_V_HH26, SLP_V_HH46, SLP_V_HH49, and SLP_V_HH50 (Fig. 1f). Based on the phage ELISA (Fig. 1e), all nine clones showed specific binding to SLP from QCD-32g58 while only SLP_V_HH2, and less strongly SLP_V_HH26, cross-reacted to SLP from strain 630. This is not surprising as the V_HH library was panned against QCD-32g58. The CDR3 length distribution among the nine antibodies isolated varied. SLP_V_HH2, SLP_V_HH5, and SLP_V_HH26 have the shortest CDR3 with 16 residues. SLP_V_HH12, SLP_V_HH22, and SLP_V_HH23 all have a significantly long CDR3, with lengths of 28, 25, and 28 residues, respectively. Many of the clones shared high sequence homology, while SLP_V_HH22 and SLP_V_HH50 contained an additional cysteine residues at position 55 and in complementarity-determining region 3 (CDR3). The presence of a cysteine at residue 55 is characteristic of V_HH subfamilies 3 and 4 (Harmsen et al. 2000). These two V_HHs were the only binders to belong to the V_HH subfamily 3 while the other V_HHs were subfamily 1. Cys55 and CDR3 Cys have the potential to form an interloop disulfide bond to restrict the fold of the relatively long CDR3 and enhance the stability of the antibodies (Govaert et al. 2012; Kim et al. 2014). This indeed was shown to be the case for both SLP_V_HH22 and SLP_V_HH50 by MS-based disulfide bond mapping experiments (Fig. 1g; Table S1). However, and unexpectedly, disulfide bond mapping also revealed that these noncanonical Cys residues were also involved in forming other, unusual disulfide linkages. In SLP_V_HH22, Cys55 and CDR3 Cys form disulfide linkages

with Cys23, which typically forms a highly conserved disulfide linkage with Cys104 in V_HHs, and similarly in SLP_V_HH50, Cys55 forms a disulfide linkage with Cys104.

Expression and biophysical characterization of SLP-binding V_HHs

The nine SLP-binding V_HHs isolated from panning were subcloned, expressed, and purified. We observed high and variable expression yields of the clones (15–75 mg/l of bacterial culture). Purified V_HHs were subjected to SEC analysis, and all were nonaggregating monomers as expected, with a mean \pm SD M_{app} of 15.9 \pm 2.4, similar to the mean \pm SD theoretical mass of 16.3 \pm 0.6 expected for monomeric V_HHs (Fig. S2a; Table 1). We further characterized the panel of V_HHs by determining midpoint unfolding temperatures (T_{ms}) by CD spectroscopy and V_HH sensitivities to the major gastrointestinal enzyme pepsin by proteolytic digestion assays. Both techniques provide valuable information on V_HH stability and aid in the selection of lead candidates. From the heat-induced unfolding curves, the V_HH T_{ms} s ranged from 62.3 to 75.4 °C (Fig. S2b; Table 1) with all V_HHs folded at physiological temperatures. Antibody unfolding followed a single phase transition as expected. Next, all V_HHs were subjected to a pepsin digestion assay at pH 2.0, beginning with a biologically relevant concentration of pepsin at 100 $\mu\text{g}/\text{ml}$ (Fig. S3). Under digestion conditions, the V_HHs exhibited a loss of the C-terminal tag, consistent with our previous findings (Hussack et al. 2011b; To et al. 2005), and therefore lower bands corresponding to a M that is \sim 2 kDa less than the band corresponding to the full-length V_HH are considered as resistant to enzymatic digestion. As expected, resistance to pepsin decreased as a function of enzyme concentration (Table 1; Fig. S3). High pepsin resistance was observed at lower pepsin concentrations and the majority of V_HHs (five out of nine) showed moderate to high resistance at 25 $\mu\text{g}/\text{ml}$ pepsin concentration. SLP_V_HH2 and SLP_V_HH22 showed the greatest pepsin resistance with an average of 12 \pm 3.1 % and 19.6 \pm 0.8 % V_HH remaining after digestion for 1 h with 100 $\mu\text{g}/\text{ml}$ of enzyme, respectively (Table 1). At lower pepsin concentrations (50 $\mu\text{g}/\text{ml}$), 15.3 \pm 5.0 % of SLP_V_HH2, 46.5 \pm 10.0 % of SLP_V_HH22, 21.9 \pm 9.8 % of SLP_V_HH23 and 2.8 \pm 2.0 % of SLP_V_HH12 remained undigested after 1 h.

Binding analysis of V_HHs to SLPs

For affinity determination, monomeric fractions of V_HHs collected from the SEC column were analyzed by SPR. V_HHs were injected over CM5-immobilized and SEC-purified QCD-32g58 SLP, 630 SLP, and the QCD-32g58 LMW subunit, at various concentrations to characterize the binding specificity and affinity (Fig. 2a, b). In the first experiment, all nine V_HHs were shown to bind QCD-32g58 SLP

Table 1 Summary of V_HH molecular mass, thermal stability, and pepsin resistance data

V _H H	<i>M</i> (kDa)	<i>M</i> _{app} (kDa)	<i>T</i> _m (°C)	Pepsin resistance (%) ^a		
				100 µg/ml	10 µg/ml	1.25 µg/ml
SLP_V _H H2	15.71	14.5	62.3	12.0±3.1	55.3±13.1	99.0±1.3
SLP_V _H H5	15.61	14.2	70.3	0	10.3±1.5	76.1±15
SLP_V _H H12	17.00	16.6	73.7	0	77.8±3.9	99.4±1.9
SLP_V _H H22	16.38	17.3	74.6	19.6±0.8	83.1±3.3	99.0±1.5
SLP_V _H H23	17.02	19.1	75.4	0	93.4±5.9	97.2±1.7
SLP_V _H H26	15.72	14.2	71.9	0	50.8±2.5	96.6±0.1
SLP_V _H H46	15.83	16.6	66.3	0	55.6±4.5	96.6±1.6
SLP_V _H H49	16.71	11.9	64.8	0	0	59.7±14.2
SLP-V _H H50	16.25	18.7	70.3	0	15.9±7.9	89.9±3.1

M theoretical (formula) molecular mass, *M*_{app} apparent molecular mass determined by SEC, *T*_m melting temperature

^a Percent V_HH (mean±SE) remaining after digestion for 1 h at 37 °C and pH 2.0 with 100, 10, or 1.25 µg/ml of pepsin (*n*=3)

(Fig. 2a; Table 2). None of the V_HHs bound to the reference surface on which a similar amount of a control protein was immobilized (data not shown). *K*_Ds were determined from kinetic rate constants (SLP_V_HH5, SLP_V_HH12, SLP_V_HH23, and SLP_V_HH46) or by steady-state analysis (SLP_V_HH2, SLP_V_HH22, SLP_V_HH26, SLP_V_HH49, and SLP_V_HH50). The V_HHs SLP_V_HH5, SLP_V_HH12, SLP_V_HH23, and SLP_V_HH46 had the highest affinities to QCD-32g58 SLP (*K*_Ds of 3–6 nM). SLP_V_HH12 and SLP_V_HH23 required the use of 50 mM NaOH for their complete dissociation from the QCD-32g58 SLP surface, which resulted in loss of surface activity; therefore, a fresh surface was made, and only a single

injection of each was used to analyze the binding activity of these two V_HHs. SLP_V_HH49 and SLP_V_HH50 had affinities of 48 and 75 nM, respectively. SLP_V_HH2, SLP_V_HH22, and SLP_V_HH26 had the weakest affinities to QCD-32g58 SLP with *K*_Ds of 230, 180, and 580 nM, respectively. These three V_HHs, as well as SLP_V_HH49, showed a complex binding pattern to QCD-32g58 SLP in that at low antibody concentrations, high-affinity binding was observed, while at high antibody concentrations lower affinity binding was observed, which maybe an indicator of antigen heterogeneity. Collectively, the SPR data confirmed the ability of the V_HHs to bind QCD-32g58 SLP.




Fig. 2 Characterization of V_HH binding to SLPs. **a, b** SPR sensorgrams illustrating the binding of V_HHs to immobilized QCD-32g58 SLP (**a**) and QCD-32g58 LMW SLP (**b**). **c** Western blots demonstrating that a subset

of V_HHs recognizes a linear epitope on the LMW subunit of QCD-32g58 SLP. *QCD* QCD-32g58

Table 2 SLP-specific V_HH binding data

V _H H	QCD-32g58 SLP				QCD-32g58 LMW SLP ^a			
	k_{on} (/M/s)	k_{off} (/s)	K_{D} (nM)	R_{max} (RU)	k_{on} (/M/s)	k_{off} (/s)	K_{D} (nM)	R_{max} (RU)
SLP_V _H H2	n.d. ^b	n.d. ^b	230	277	1.5×10^5	1.3×10^{-2}	90	26
SLP_V _H H5	8.2×10^4	4.6×10^{-4}	6	100	1.4×10^5	4.1×10^{-4}	3	151
SLP_V _H H12	1.2×10^5	3.4×10^{-4}	3	142	1.4×10^5	1.2×10^{-4}	1	131
SLP_V _H H22	n.d. ^b	n.d. ^b	180	100	1.3×10^5	1.1×10^{-3}	8	114
SLP_V _H H23	9.4×10^4	3.7×10^{-4}	4	98	1.1×10^5	3.2×10^{-4}	3	72
SLP_V _H H26	n.d. ^b	n.d. ^b	580	288	2.1×10^{5c}	9.7×10^{-2c}	460 ^c	5 ^c
SLP_V _H H46	1.1×10^5	3.4×10^{-4}	3	83	1.5×10^5	3.2×10^{-4}	2	181
SLP_V _H H49	n.d. ^b	n.d. ^b	48	197	5.9×10^5	1.2×10^{-2}	20	231
SLP-V _H H50	n.d. ^b	n.d. ^b	75	175	1.9×10^5	2.7×10^{-3}	14	154

^a Binding kinetics were determined from 200 nM V_HH injections as a binding screen

^b A steady-state model was used to obtain the K_{D} . Therefore, rate constants are not determined (n.d.)

^c The affinity and rate constants should be interpreted with caution as the experimental R_{max} is very low, and multiple injection are required to confirm the values

Next, we expanded our SPR analyses to determine if the V_HHs cross-reacted to 630 SLP. In a similar approach to the QCD-32g58 SLP, 630 SLP were immobilized on a CM5 sensor chip and V_HHs injected at various concentrations. Consistent with our earlier phage ELISA results (Fig. 1e), only SLP_V_HH2 and SLP_V_HH26 bound 630 SLP (data not shown). The affinities of SLP_V_HH2 and SLP_V_HH26 to 630 SLP were 1 and 2 μM, respectively, indicating a ~5-fold weaker binding affinity to 630 SLP than QCD-32g58 SLP.

Finally, we set out to explore the nature of the QCD-32g58 SLP epitope recognized by the V_HHs, specifically if they bound the HMW or LMW SLP subunit. As previously shown (Fig. 1c), we were unable to purify the HMW SLP subunit and purified only a small amount of the QCD-32g58 LMW SLP subunit which limited our SPR analysis against the LMW SLP to a single concentration screen. At 200 nM V_HH concentrations, all of our V_HHs bound the QCD-32g58 LMW subunit (Fig. 2b; Table 2). A similar affinity rank pattern to the full SLP was observed: SLP_V_HH5, SLP_V_HH12, SLP_V_HH23, and SLP_V_HH46 had the lowest K_{D} s of all V_HHs tested, SLP_V_HH2 and SLP_V_HH26 had the highest K_{D} s, and the remaining V_HHs had intermediate K_{D} s. Interestingly, the V_HHs bound with higher affinities to the LMW SLP than the full SLP, suggesting a more optimal epitope presentation on the SPR chip for the LMW SLP. Collectively, the SPR binding data indicated the epitopes recognized by anti-SLP V_HHs reside entirely in the LMW subunit of QCD-32g58 SLP, and that some level of cross-reactivity to 630 SLP, presumably with the LMW subunit, was evident for a subset of the V_HHs. These findings are consistent with earlier reports that showed the LMW SLP subunit is immunodominant (Spigaglia et al. 2011) and that cross-reactive antibodies to the LMW SLP subunit from different *C. difficile* ribotypes

are rare due to the low amino acid sequence homology (Calabi et al. 2001). To determine if the QCD-32g58 SLP epitope recognized by the V_HHs was linear or conformational, a denaturing SDS-PAGE-Western blot was performed. QCD-32g58 SLPs were separated in an SDS-PAGE gel under reducing conditions, transferred to a PVDF membrane, and probed with individual V_HHs followed by detection with an anti-His₆ IgG conjugated to alkaline phosphatase (Fig. 2c). A nontransferred SDS-PAGE was run to demonstrate the presence of both HMW and LMW QCD-32g58 SLP subunits in the samples (Fig. 2c, left panel). Moreover, a Western blot performed against transferred V_HHs confirmed all V_HHs had their His₆ tag. The V_HHs SLP_V_HH5, SLP_V_HH12, SLP_V_HH23, SLP_V_HH46, and SLP_V_HH49 bound the LMW subunit of QCD-32g58 SLP, consistent with our SPR results (Fig. 2b), and indicating that these V_HHs recognized a linear epitope. The remaining V_HHs were weakly positive, or negative altogether, by Western blot for binding to the LMW subunit of QCD-32g58 SLP, indicating that they may recognize conformational epitopes, or have too low of an affinity and/or k_{off} s too rapid to produce a detectible signal.

Binding of V_HHs to *C. difficile* cells

ELISA was used to determine the ability of each V_HH to bind to a number of *C. difficile* clinical isolates. All SLP-specific V_HHs in this study bound bacterial cells of strain QCD-32g58 (Fig. 3a). In addition, strong reactivity of each V_HH to the bacterial cell surface of a number of other *C. difficile* isolates which belong to the same 027 hypervirulent ribotype (BI-1, BI-7, 196, R20291) as well as ribotype 001 (strain 001_01) was observed. In contrast, V_HH reactivity to the cell surface of representative strains from other ribotypes (012, 017, 023, and




Fig. 3 SLP-specific V_HHs bind *C. difficile* cells and inhibit motility. **a** Whole cell ELISA demonstrating the binding of V_HHs to various *C. difficile* strains. **b** *C. difficile* (QCD-32g58) stabs after 23 h comparing the effects of 25 and 50 μg/ml V_HH concentrations on

bacterial motility. SLP_V_HH5, SLP_V_HH46, and SLP_V_HH50 showed inhibition of *C. difficile* motility, denoted with arrows at the tip of the stabs

078) was far more restricted, suggesting considerable diversity in the LMW SLP epitopes displayed among distinct lineages of *C. difficile*. Interestingly, SLP_V_HH5 was able to recognize all *C. difficile* isolates tested, representing a number of distinct ribotypes. While both SLP_V_HH2 and SLP_V_HH26 were shown to cross-react to 630 SLP in phage ELISA and SPR assays, it was only SLP_V_HH2 that cross-reacted to 630 SLP in cell binding assays.

C. difficile motility assays

Despite a lack of evidence in the literature relating SLP function to bacterial motility, we nonetheless sought to test the ability of SLP-specific V_HHs to inhibit *C. difficile* (QCD-32g58 strain) motility. Culture tubes containing BHI-agar supplemented with V_HHs at either 25 μg/ml (~1.5 μM) or 50 μg/ml (~3 μM) were inoculated with stabs of *C. difficile* and cultured for 23 h. Growth was monitored and photographed 23 h postinoculation (Fig. 3b). Motile cells displayed a diffuse spreading flare of growth at the bottom of the inoculating stab. The results demonstrated that at 23 h postinoculation using 25-μg/ml antibody concentrations, SLP_V_HH5 and SLP_V_HH46 completely inhibited *C. difficile* motility. SLP_V_HH50 showed slight inhibition of

motility at 25 μg/ml. The remaining V_HHs did not inhibit motility at concentrations of 25 μg/ml. To test whether motility inhibition was concentration dependent, we doubled the antibody concentration to 50 μg/ml (Fig. 3b). Similar to the lower concentration, SLP_V_HH5 and SLP_V_HH46 clearly inhibited *C. difficile* motility. Increasing the concentration of SLP_V_HH50 to 50 μg/ml resulted in complete inhibition of *C. difficile* motility.

Discussion

The outer surface of many bacteria is covered in a proteinaceous coat called the S-layer (surface layer) that is involved in growth, function, and interaction with the host (Fagan and Fairweather 2014). In Gram-positive species, such as *C. difficile*, SLPs have been shown to play a role in adherence to gastrointestinal tract cells and extracellular matrix components (Calabi et al. 2002; Takumi et al. 1991), and recently, SLPs were shown to have a role in activating innate and adaptive immunity through TLR4 (Ryan et al. 2011) and induce pro-inflammatory cytokines (Bianco et al. 2011; Collins et al. 2014). It has been known for several years that patients with recurrent episodes of *C. difficile* have significantly lower anti-

SLP IgM titers than patients experiencing a single episode of *C. difficile* infection (Drudy et al. 2004). In addition, active immunization of hamsters with SLPs elucidated partial protection when challenged with *C. difficile* (Ni Eidhin et al. 2008). Collectively, this suggests that SLPs may have a critical role in *C. difficile* pathogenesis and virulence in humans, making them targets for diagnostic probes, vaccine development and novel therapeutic agents. In *C. difficile*, mature SLPs consist of HMW and LMW subunits which are produced by proteolytic cleavage of a single polypeptide chain (SlpA). In a mature SLP, the LMW subunit is displayed toward the environment and shows higher sequence variability than the HMW subunit (Calabi and Fairweather 2002; Merrigan et al. 2013).

To explore the use of antibodies targeting novel *C. difficile* virulence factors, we produced high-affinity llama V_HHs to *C. difficile* SLPs. We isolated SLPs from the hypervirulent QCD-32g58 strain (027 ribotype) and the 630 reference strain (012 ribotype), immunized a llama with both simultaneously, isolated several V_HHs, and characterized these antibodies. Immunization with SLPs generated a strong heavy-chain antibody immune response in the llama, indicating the SLPs were very immunogenic. From a phage display library panned with SLPs from QCD-32g58, nine unique V_HHs were isolated. By phage ELISA and SPR, all recognized QCD-32g58 SLP, while two (SLP_V_HH2 and SLP_V_HH26) cross-reacted to 630 SLP, with at least more than half of the V_HHs recognizing linear epitopes. SPR binding of V_HHs revealed high-affinity binding to QCD-32g58 SLP with K_{DS} as low as 3–6 nM, but nonetheless, several V_HHs also had significantly higher K_{DS} , as high as 580 nM, a K_D range pattern frequently seen with V_HHs obtained from immune V_HH phage display libraries. Interestingly, the four V_HHs with the highest affinities (3–6 nM) all recognize linear epitopes. Despite immunizing and panning with the QCD-32g58 whole SLP, all of the V_HHs targeted the highly variable LMW subunit. The HMW subunit is conserved across *C. difficile* isolates and the LMW subunit is considerably more variable (Calabi and Fairweather 2002; Merrigan et al. 2013). In agreement with our findings, between the LMW and HMW subunits, the LMW one has been shown to be the immunodominant antigen elsewhere (Ausiello et al. 2006; Péchiné et al. 2007).

With respect to thermostability, V_HHs showed T_m s as high as 75 °C, although engineered V_HHs with higher T_m s have been previously reported, in the range of 79–94 °C (Hussack et al. 2011b; Zabetakis et al. 2014). V_HHs also showed significant resistance to the GI enzyme pepsin with two V_HHs having pepsin resistance as high as 20 % at a physiologically relevant pepsin concentration (100 µg/ml). Noticeably, three out of the four V_HHs that showed pepsin resistance at a relatively high enzyme concentration (50 µg/ml) have the highest T_m s (73.7–75.4 °C), and SLP_V_HH22, which was the most resistant V_HH, had a pair of Cys at positions 55 and in CDR3

that formed an extra disulfide linkage. Previously, a positive correlation was found between pepsin resistance and T_m , and mutations that increased T_m also increased pepsin resistance (Hussack et al. 2011b). The extra noncanonical disulfide linkage in SLP_V_HH22 may be a contributor to its high T_m and/or pepsin resistance. Previously, similar noncanonical (inter-CDR1-CDR3; inter-CDR2-CDR3) disulfide linkages were shown to increase the stability of V_HHs (Govaert et al. 2012; Zabetakis et al. 2014). In particular, a disulfide linkage formed between a pair of Cys residues at positions 55 and in CDR3 improved the T_m of a V_HH by several degrees (Zabetakis et al. 2014). However, we find that in addition to forming the expected noncanonical disulfide linkage between them, Cys55 and CDR3 Cys also pair up with Cys23 or Cys104—which are involved in a highly conserved canonical disulfide linkage in V_HHs—to form unusual disulfide linkages not reported previously. Whether these unusual disulfide linkages are the result of heterologous expression in *E. coli* is not clear to us. It is also unclear if they are present in significant proportions of the V_HH population.

We tested the ability of V_HHs to bind *C. difficile* whole cells in ELISA, which presents the SLP protein in a more natural context for antibody binding. All nine V_HHs bound QCD-32g58 cells and, not surprisingly, all other 027 ribotype strains tested, including BI-1, BI-7, 196, and R20291, which have identical LMW subunit SLP sequences to QCD-32g58. These results confirm the feasibility of using purified, out-of-natural-context SLP as an immunogen and target antigen for panning experiments for obtaining anti-SLP antibodies that recognize parent cells equally well. As well, the panel of V_HHs all bound to a 001 ribotype strain, indicating that at least the LMW subunit of 001 ribotype strain should have high sequence identity to the SLP LMW subunits from the aforementioned 027 ribotypes. SLP_V_HH2 showed binding to 630, which was expected given the evidence of cross-reactivity in ELISA and SPR. SLP_V_HH26 did not show binding to 630 cells, despite earlier ELISA and SPR evidence showing binding to 630 SLPs. Interestingly, SLP_V_HH5 bound all ribotypes tested in the cell ELISA format, indicating the antibody is broadly cross-reactive. Why SLP_V_HH5 failed to recognize 630 SLPs in phage ELISA and SPR is not entirely clear, but it could be due to the fact that immobilizing the SLP prevented antibody binding by masking or changing the conformation of the epitope. Differential epitope presentations may also account for binding inconsistencies observed for SLP_V_HH26 between phage ELISA/SPR assays and cell ELISA assay. The remaining V_HHs did not bind cells representative of 012, 017, 023 or 078 ribotypes. The low frequency of cross-reactive V_HHs may not be surprising given the low amino acid identity among SLP LMW subunits from different ribotypes. We speculate that at least six different epitopes are being recognized by our pool of V_HHs, given that there are five different specificities inferred from cell binding, motility

and ELISA/SPR assays, one represented by SLP_V_HH2, one by SLP_V_HH5, one by SLP_V_HH26 that cross-reacted to 630 strain in phage ELISA/SPR, one by SLP_V_HH46 and SLP_V_HH50 that inhibited motility, and one represented by the remaining V_HHs (SLP_V_HH12, SLP_V_HH22, SLP_V_HH23, and SLP_V_HH49). This latter group can be divided into those binding a linear epitope and those binding a conformational epitope as determined by Western blotting.

Despite their variability, alignment of LMW SLP amino acid sequences from several *C. difficile* ribotypes reveal stretches of conserved residues that could represent epitopes for cross-reactive antibody binding (Fig. S4). Specifically, residues 8–11, 72–83, 249–261, 264–275, and 299–321, numbered based on the 630 sequence, show significant homology across all aligned ribotypes (Fagan et al. 2009). Based on LMW SLP structural data, the LMW SLP is composed of domain 1 (residues 1–87 and residues 242–248) and domain 2 (residues 97–233), with domain 1 facing toward the bacterial cell wall and the HMW subunit, while domain 2 is orientated away, toward the environment (Fagan et al. 2009). The residues of domain 2 show the most variability among ribotypes (Fig. S4) and are also likely the most accessible for antibody binding given they extend away from the bacterial surface. In the case of the broadly cross-reactive SLP_V_HH5 antibody, it is possible that even though domain 1 of the LMW SLP faces inward toward the cell wall and is in close proximity to the HMW SLP interaction domain, domain 1 residues remain accessible for binding. Further studies on this antibody, including co-crystallization structure determination, could reveal the true nature of the LMW epitope.

Somewhat surprisingly, in agar-stab motility assays, several V_HHs were capable of inhibiting motility of QCD-32g58 cells. In particular, SLP_V_HH5 and SLP_V_HH46 were capable of inhibiting motility at both high and low antibody concentrations. To a lesser degree, SLP_V_HH50 was also found to inhibit motility. Higher affinity, faster k_{on} /slower k_{off} and/or the nature of epitope of SLP_V_HH5 and SLP_V_HH46 may be responsible for their greater motility inhibition potency compared to SLP_V_HH50 (based on Western blot and cell-binding experiments, SLP_V_HH5 and SLP_V_HH46 have different epitopes than SLP_V_HH50). There are a limited number of reports of polyclonal antibody and mAb preparations targeting *C. difficile* SLPs; however, none have examined the ability of antibodies to inhibit *C. difficile* motility. Takumi et al. (1991) produced anti-SLP Fab fragments and used them to inhibit the adherence of *C. difficile* to human cervical cancer cells and mouse fibroblast cells. O'Brien et al. (2005) showed that the injection of hamsters with antibodies to SLPs prolonged the survival of *C. difficile*-infected hamsters. More recently, anti-HMW SlpA and anti-LMW SlpA polyclonal antiserum was shown to reduce *C. difficile* strain 630 adherence to C2_{BBE} human colonic epithelial cells although the precise mechanism was not defined (Merrigan

et al. 2013). While our study is unique in that we appear to inhibit motility through targeting *C. difficile* SLPs, others have found motility-inhibiting affinity reagents by targeting an alternative bacterial cell surface structure, namely the lipopolysaccharide (LPS). A mAb that bound the LPS of *Salmonella enterica* was shown to inhibit flagellum-based motility (Forbes et al. 2008). Similarly, P22sTsp, a phage tailspike protein that binds to LPS was also able to inhibit the motility of *Salmonella enterica* serovar Typhimurium (Waseh et al. 2010). As would be expected an anti-flagellin mAb inhibited the motility of multi-drug resistant *Pseudomonas aeruginosa* and curbed lethality in mice (Adawi et al. 2012). In another study, anti-*P. aeruginosa* flagellin V_HHs inhibited the motility and biofilm formation of *P. aeruginosa* (Adams et al. 2014). Similarly an anti-*Campylobacter jejuni* flagellin V_HH inhibited the motility of *C. jejuni* (Hussack et al. 2014; Riazi et al. 2013). To date, there is no known report of SLP interactions with motility factors in *C. difficile* and SLPs remain the primary adherence factors of *C. difficile*. However, the theme of blocking a surface antigen which is high in abundance, wherein motility is reduced, is presented in this study and warrants further investigation. Our data suggests that antibodies binding to *C. difficile* SLPs may provide some form of steric hindrance to the effective functioning of the flagellar motility apparatus. Continued studies on the structure and function of *C. difficile* SLPs and their role in host-pathogen interactions, as well as nature of the LMW epitope recognized by broadly cross-reactive SLP antibodies which inhibit motility, will help in elucidating this unusual interaction between two key surface structures. Whether our SLP-specific V_HHs interfere with cell growth and biofilm formation warrants further investigation.

In conclusion, we have isolated a panel of high-affinity V_HHs that target the LMW SLP subunit of *C. difficile* QCD-32g58. Many of the V_HHs recognized several strains within the 027 ribotype, which is the predominant hypervirulent ribotype seen in hospital-acquired (nosocomial) *C. difficile* infections. One V_HH (SLP_V_HH5) additionally recognized two strains from ribotypes 017 and 078 which are recognized as emerging PCR ribotypes implicated in recent outbreaks with increased disease severity (Cheknis et al. 2009; Hunt and Ballard 2013). Of additional significance, a subset of four V_HHs (SLP_V_HH5, SLP_V_HH12, SLP_V_HH23, and SLP_V_HH46) possessed high affinities, a similar set (SLP_V_HH5, SLP_V_HH46, and SLP_V_HH50) inhibited motility and two (SLP_V_HH12 and SLP_V_HH23) demonstrated strong resistance to the GI protease pepsin. Affinity maturation combined with a disulfide engineering approach described previously (Hussack et al. 2011b; Hussack et al. 2014; Saerens et al. 2008) can be employed to further increase their affinities, motility inhibition capability and resistance to GI proteases, making them suitable oral/GI therapeutics against CDAD or useful agents in the validation of SLP as a

vaccine target. A combination therapy approach involving the present anti-SLP V_HHs and previously described toxin A- and toxin B-specific V_HHs (Hussack et al. 2011a; Yang et al. 2014) also appears attractive.

Acknowledgments We thank W. Ding and J. F. Kelly (National Research Council Canada, Ottawa, ON, Canada) for performing mass spectrometry analysis, A. Dascal (Jewish General Hospital, Montreal, QC, Canada) for providing strain QCD-32g58, and B. Wren (LSHTM, London, UK) for providing strains 630, R20291, BI-1, BI-7, 196, 001_01, M68, Cd305, and M120.

Conflict of interest The authors declare that they have no conflict of interest.

Ethical statement All procedures involving llamas and their care in this study were approved by the Animal Care Committee of Cedarlane licensed by the Ontario Ministry of Agriculture, Food and Rural Affairs.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Adams H, Horrevoets WM, Adema SM, Carr HE, van Woerden RE, Koster M, Tommassen J (2014) Inhibition of biofilm formation by camelid single-domain antibodies against the flagellum of *Pseudomonas aeruginosa*. *J Biotechnol* 186:66–73
- Adawi A, Bisignano C, Genovese T, Filocamo A, Khouri-Assi C, Neville A, Feuerstein GZ, Cuzzocrea S, Neville LF (2012) In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant *Pseudomonas aeruginosa*. *Int J Mol Med* 30:455–464
- Åkerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, Burman LG (2008) Increased sporulation rate of epidemic *Clostridium difficile* Type 027/NAP1. *J Clin Microbiol* 46:1530–1533
- Ausiello CM, Cerquetti M, Fedele G, Spensieri F, Palazzo R, Nasso M, Frezza S, Mastrantonio P (2006) Surface layer proteins from *Clostridium difficile* induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. *Microbes Infect* 8:2640–2646
- Bianco M, Fedele G, Quattrini A, Spigaglia P, Barbanti F, Mastrantonio P, Ausiello CM (2011) Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent *Clostridium difficile* strains. *J Med Microbiol* 60:1162–1167
- Bourgault AM, Lamothe F, Loo VG, Poirier L (2006) In vitro susceptibility of *Clostridium difficile* clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. *Antimicrob Agents Chemother* 50:3473–3475
- Calabi E, Fairweather N (2002) Patterns of sequence conservation in the S-layer proteins and related sequences in *Clostridium difficile*. *J Bacteriol* 184:3886–3897
- Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, Dell A, Dougan G, Fairweather N (2001) Molecular characterization of the surface layer proteins from *Clostridium difficile*. *Mol Microbiol* 40:1187–1199
- Calabi E, Calabi F, Phillips AD, Fairweather NF (2002) Binding of *Clostridium difficile* surface layer proteins to gastrointestinal tissues. *Infect Immun* 70:5770–5778
- Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ (2008) The biology and future prospects of antivirulence therapies. *Nat Rev Microbiol* 6:17–27
- Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S, Gerding DN (2009) Distribution of *Clostridium difficile* strains from a North American, European and Australian trial of treatment for *C. difficile* infections: 2005–2007. *Anaerobe* 15:230–233
- Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol* 3:541–548
- Collins LE, Lynch M, Marszalowska I, Kristek M, Rochfort K, O’Connell M, Windle H, Kelleher D, Loscher CE (2014) Surface layer proteins isolated from *Clostridium difficile* induce clearance responses in macrophages. *Microbes Infect* 16:391–400
- Drudy D, O’Donoghue DP, Baird A, Fenelon L, O’Farrelly C (2001) Flow cytometric analysis of *Clostridium difficile* adherence to human intestinal epithelial cells. *J Med Microbiol* 50:526–534
- Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, Kelly CP (2004) Human antibody response to surface layer proteins in *Clostridium difficile* infection. *FEMS Immunol Med Microbiol* 41:237–242
- Dubberke ER, Olsen MA (2012) Burden of *Clostridium difficile* on the healthcare system. *Clin Infect Dis* 55(Suppl 2):S88–S92
- Dubreuil JD, Logan SM, Cabbage S, Eidhin DN, McCubbin WD, Kay CM, Beveridge TJ, Ferris FG, Trust TJ (1988) Structural and biochemical analyses of a surface array protein of *Campylobacter fetus*. *J Bacteriol* 170:4165–4173
- Dupuy B, Govind R, Antunes A, Matamouros S (2008) *Clostridium difficile* toxin synthesis is negatively regulated by TcdC. *J Med Microbiol* 57:685–689
- Fagan RP, Fairweather NF (2014) Biogenesis and functions of bacterial S-layers. *Nat Rev Microbiol* 12:211–222
- Fagan RP, Albesa-Jove D, Qazi O, Svergun DI, Brown KA, Fairweather NF (2009) Structural insights into the molecular organization of the S-layer from *Clostridium difficile*. *Mol Microbiol* 71:1308–1322
- Forbes SJ, Eschmann M, Mantis NJ (2008) Inhibition of *Salmonella enterica* serovar Typhimurium motility and entry into epithelial cells by a protective antilipopolysaccharide monoclonal immunoglobulin A antibody. *Infect Immun* 76:4137–4144
- Forgetta V, Oughton MT, Marquis P, Brukner I, Blanchette R, Haub K, Magrini V, Mardis ER, Gerding DN, Loo VG, Miller MA, Mulvey MR, Rupnik M, Dascal A, Dewar K (2011) Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of *Clostridium difficile*. *J Clin Microbiol* 49:2230–2238
- Ghantaji SS, Sail K, Lairson DR, DuPont HL, Garey KW (2010) Economic healthcare costs of *Clostridium difficile* infection: a systematic review. *J Hosp Infect* 74:309–318
- Ghose C (2013) *Clostridium difficile* infection in the twenty-first century. *Emerg Microbes Infect* 2:e62
- Giannasca PJ, Warny M (2004) Active and passive immunization against *Clostridium difficile* diarrhea and colitis. *Vaccine* 22:848–856
- Gilca R, Hubert B, Fortin E, Gaulin C, Dionne M (2010) Epidemiological patterns and hospital characteristics associated with increased incidence of *Clostridium difficile* infection in Québec, Canada, 1998–2006. *Infect Control Hosp Epidemiol* 31:939–947
- Govaert J, Pellis M, Deschacht N, Vincke C, Conrath K, Muyltermans S, Saerens D (2012) Dual beneficial effect of interloop disulfide bond for single domain antibody fragments. *J Biol Chem* 287:1970–1979
- Grogono-Thomas R, Dworkin J, Blaser MJ, Newell DG (2000) Roles of the surface layer proteins of *Campylobacter fetus* subsp. *fetus* in ovine abortion. *Infect Immun* 68:1687–1691
- Hamadeh RM, Estabrook MM, Zhou P, Jarvis GA, Griffiss JM (1995) Anti-Gal binds to pili of *Neisseria meningitidis*: the

- immunoglobulin A isotype blocks complement-mediated killing. *Infect Immun* 63:4900–4906
- Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. *Appl Microbiol Biotechnol* 77:13–22
- Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, de Geus B (2000) Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. *Mol Immunol* 37:579–590
- Harmsen MM, van Solt CB, Fijten HP, van Keulen L, Rosalia RA, Weerdmeester K, Cornelissen AH, De Bruin MG, Eble PL, Dekker A (2007) Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. *Vet Microbiol* 120:193–206
- Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 23:1126–1136
- Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. *Trends Biotechnol* 21:484–490
- Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, Dionne M, Lorange M (2007) A portrait of the geographic dissemination of the *Clostridium difficile* North American pulsed-field type 1 strain and the epidemiology of *C. difficile*-associated disease in Québec. *Clin Infect Dis* 44:238–244
- Hunt JJ, Ballard JD (2013) Variations in virulence and molecular biology among emerging strains of *Clostridium difficile*. *Microbiol Mol Biol Rev* 77:567–581
- Hussack G, Tanha J (2010) Toxin-specific antibodies for the treatment of *Clostridium difficile*: current status and future perspectives. *Toxins* 2:998–1018
- Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R, Tanha J (2011a) Neutralization of *Clostridium difficile* toxin A with single-domain antibodies targeting the cell receptor binding domain. *J Biol Chem* 286:8961–8976
- Hussack G, Hiramata T, Ding W, Mackenzie R, Tanha J (2011b) Engineered single-domain antibodies with high protease resistance and thermal stability. *PLoS One* 6:e28218
- Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, Tanha J (2012) Isolation and characterization of *Clostridium difficile* toxin-specific single-domain antibodies. *Methods Mol Biol* 911:211–239
- Hussack G, Riazzi A, Ryan S, van Faassen H, MacKenzie R, Tanha J, Arbabi-Ghahroudi M (2014) Protease-resistant single-domain antibodies inhibit *Campylobacter jejuni* motility. *Protein Eng Des Sel* 27:191–198
- Jank T, Aktories K (2008) Structure and mode of action of clostridial glucosylating toxins: the ABCD model. *Trends Microbiol* 16:222–229
- Jank T, Giesemann T, Aktories K (2007) Rho-glucosylating *Clostridium difficile* toxins A and B: new insights into structure and function. *Glycobiology* 17:15R–22R
- Janvilisri T, Scaria J, Thompson AD, Nicholson A, Limbago BM, Arroyo LG, Songer JG, Gröhn YT, Chang YF (2009) Microarray identification of *Clostridium difficile* core components and divergent regions associated with host origin. *J Bacteriol* 191:3881–3891
- Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to *Clostridium difficile* infection. *J Infect* 61:1–8
- Kim DY, Ding W, Tanha J (2012a) Solubility and stability engineering of human V_H domains. *Methods Mol Biol* 911:355–372
- Kim DY, Kandalaf H, Ding W, Ryan S, van Faassen H, Hiramata T, Foote SJ, MacKenzie R, Tanha J (2012b) Disulfide linkage engineering for improving biophysical properties of human V_H domains. *Protein Eng Des Sel* 25:581–589
- Kim DY, Hussack G, Kandalaf H, Tanha J (2014) Mutational approaches to improve the biophysical properties of human single-domain antibodies. *Biochim Biophys Acta* 1844:1983–2001
- Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A (2005) A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 353:2442–2449
- Lynch SV, Wiener-Kronish JP (2008) Novel strategies to combat bacterial virulence. *Curr Opin Crit Care* 14:593–599
- MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, Henwick S (2006) Molecular analysis of *Clostridium difficile* PCR ribotype 027 isolates from Eastern and Western Canada. *J Clin Microbiol* 44:2147–2152
- Mauri PL, Pietta PG, Maggioni A, Cerquetti M, Sebastianelli A, Mastrantonio P (1999) Characterization of surface layer proteins from *Clostridium difficile* by liquid chromatography/electrospray ionization mass spectrometry. *Rapid Commun Mass Spectrom* 13:695–703
- Merrigan MM, Venugopal A, Roxas JL, Anwar F, Mallozzi MJ, Roxas BA, Gerding DN, Viswanathan VK, Vedantam G (2013) Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of *Clostridium difficile*. *PLoS One* 8:e78404
- Monot M, Boursaux-Eude C, Thibonnier M, Vallenet D, Moszer I, Medigue C, Martin-Verstraete I, Dupuy B (2011) Reannotation of the genome sequence of *Clostridium difficile* strain 630. *J Med Microbiol* 60:1193–1199
- Ni Eidhin DB, O'Brien JB, McCabe MS, Athie-Morales V, Kelleher DP (2008) Active immunization of hamsters against *Clostridium difficile* infection using surface-layer protein. *FEMS Immunol Med Microbiol* 52:207–218
- O'Brien JB, McCabe MS, Athie-Morales V, McDonald GS, Ni Eidhin DB, Kelleher DP (2005) Passive immunisation of hamsters against *Clostridium difficile* infection using antibodies to surface layer proteins. *FEMS Microbiol Lett* 246:199–205
- Pantosti A, Cerquetti M, Viti F, Ortisi G, Mastrantonio P (1989) Immunoblot analysis of serum immunoglobulin G response to surface proteins of *Clostridium difficile* in patients with antibiotic-associated diarrhea. *J Clin Microbiol* 27:2594–2597
- Péchiné S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, Fattal E, Collignon A (2007) Diminished intestinal colonization by *Clostridium difficile* and immune response in mice after mucosal immunization with surface proteins of *Clostridium difficile*. *Vaccine* 25:3946–3954
- Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D (2004) *Clostridium difficile*-associated diarrhea in a region of Québec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* 171:466–472
- Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Québec. *Clin Infect Dis* 41:1254–1260
- Riazzi A, Strong PC, Coleman R, Chen W, Hiramata T, van Faassen H, Henry M, Logan SM, Szymanski CM, Mackenzie R, Ghahroudi MA (2013) Pentavalent single-domain antibodies reduce *Campylobacter jejuni* motility and colonization in chickens. *PLoS One* 8:e83928
- Ryan A, Lynch M, Smith SM, Amu S, Nel HJ, McCoy CE, Dowling JK, Draper E, O'Reilly V, McCarthy C, O'Brien J, Ni Eidhin D, O'Connell MJ, Keogh B, Morton CO, Rogers TR, Fallon PG, O'Neill LA, Kelleher D, Loscher CE (2011) A role for TLR4 in *Clostridium difficile* infection and the recognition of surface layer proteins. *PLoS Pathog* 7:e1002076
- Saerens D, Conrath K, Govaert J, Muyldermans S (2008) Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. *J Mol Biol* 377:478–488
- Sara M, Sleytr UB (2000) S-Layer proteins. *J Bacteriol* 182:859–868

- Schmidt C, Löffler B, Ackermann G (2007) Antimicrobial phenotypes and molecular basis in clinical strains of *Clostridium difficile*. *Diagn Microbiol Infect Dis* 59:1–5
- Sebahia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J (2006) The multidrug-resistant human pathogen *Clostridium difficile* has a highly mobile, mosaic genome. *Nat Genet* 38:779–786
- Sleytr UB, Beveridge TJ (1999) Bacterial S-layers. *Trends Microbiol* 7: 253–260
- Spigaglia P, Barbanti F, Mastrantonio P (2008) Tetracycline resistance gene *tet(W)* in the pathogenic bacterium *Clostridium difficile*. *Antimicrob Agents Chemother* 52:770–773
- Spigaglia P, Galeotti CL, Barbanti F, Scarselli M, Van Broeck J, Mastrantonio P (2011) The LMW surface-layer proteins of *Clostridium difficile* PCR ribotypes 027 and 001 share common immunogenic properties. *J Med Microbiol* 60:1168–1173
- Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebahia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW (2009) Comparative genome and phenotypic analysis of *Clostridium difficile* 027 strains provides insight into the evolution of a hypervirulent bacterium. *Genome Biol* 10:R102
- Takumi K, Susami Y, Takeoka A, Oka T, Koga T (1991) S layer protein of *Clostridium tetani*: purification and properties. *Microbiol Immunol* 35:569–575
- Tanha J, Dubuc G, Hiram T, Narang SA, MacKenzie CR (2002) Selection by phage display of llama conventional V_H fragments with heavy chain antibody V_HH properties. *J Immunol Methods* 263:97–109
- To R, Hiram T, Arbabi-Ghahroudi M, MacKenzie R, Wang P, Xu P, Ni F, Tanha J (2005) Isolation of monomeric human V_HS by a phage selection. *J Biol Chem* 280:41395–41403
- Twine SM, Reid CW, Aubry A, McMullin DR, Fulton KM, Austin J, Logan SM (2009) Motility and flagellar glycosylation in *Clostridium difficile*. *J Bacteriol* 191:7050–7062
- van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrips CT, Hammarstrom L, van Klinken BJ (2006) Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. *Vaccine* 24:4130–4137
- Virdi V, Coddens A, De Buck S, Millet S, Goddeeris BM, Cox E, De Greve H, Depicker A (2013) Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic *Escherichia coli* infection. *Proc Natl Acad Sci U S A* 110:11809–11814
- Warny M, Pépin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC (2005) Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* 366:1079–1084
- Waseh S, Hanifi-Moghaddam P, Coleman R, Masotti M, Ryan S, Foss M, MacKenzie R, Henry M, Szymanski CM, Tanha J (2010) Orally administered P22 phage tailspike protein reduces *Salmonella* colonization in chickens: prospects of a novel therapy against bacterial infections. *PLoS One* 5:e13904
- Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F, Koch-Nolte F (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. *Med Microbiol Immunol* 198:157–174
- Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H (2014) A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant *Clostridium difficile* infection in mice. *J Infect Dis* 210:964–972
- Yau KY, Dubuc G, Li S, Hiram T, Mackenzie CR, Jermutus L, Hall JC, Tanha J (2005) Affinity maturation of a V_HH by mutational hotspot randomization. *J Immunol Methods* 297:213–224
- Zabetakis D, Olson MA, Anderson GP, Legler PM, Goldman ER (2014) Evaluation of disulfide bond position to enhance the thermal stability of a highly stable single domain antibody. *PLoS One* 9:e115405